Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent influenza vaccine
- Development stage
- Phase 4
- Lead developer
- Il-Yang Pharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
IL-YANG Quadrivalent Influenza Vaccine is an inactivated, split-virion vaccine developed by Il-Yang Pharmaceutical for the prevention of seasonal influenza. It is designed to provide broad protection by targeting four distinct influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The vaccine works by inducing the production of neutralizing antibodies against the viral hemagglutinin protein, thereby preventing viral entry and infection. It is administered via intramuscular injection and has been evaluated in Phase III clinical trials for safety and immunogenicity in both adults and pediatric populations, subsequently receiving approval in South Korea.
- Brand names
- Ilyang Flu QuadrivalentIL-YANG Quadrivalent Influenza Vaccine Inj.
- Other names
- Il-Yang Quadrivalent Seasonal Influenza Vaccinequadrivalent influenza vaccine, split virion, inactivated
02
Targets
NeuraminidaseHA (Hemagglutinin)Influenza virus internal proteins
Beyond the preview
Go deeper on quadrivalent influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent influenza vaccine.